A Phase 4 interventional study of Enzalutamide and Flutamide in Prostate Cancer, sponsored by Astellas Pharma Inc. Completed at 47 sites in Japan. Open to male participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2024-12-09.
Sponsored by Astellas Pharma Inc · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies testing enzalutamide in Prostatic Neoplasms — 17 open to participants now, 38 under way, 9 of them phase 3. enzalutamide · Prostatic Neoplasms.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, this one is the 27th largest by enrollment, is one of 9 that started in 2016, is one of 7 in phase 4, and was the 69th registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →17 of the 125 studies testing enzalutamide in Prostatic Neoplasms are open now, in 12 countries. Recruiting first, the newest first:
Astellas Pharma Global Development, Inc. · Sites in Bulgaria
Ages 50–75 · Men only · Healthy volunteers
University of Michigan Rogel Cancer Center · Sites in United States
Ages 18+ · Men only
Novartis Pharmaceuticals · Sites in United States, Australia, France and 4 more countries
Ages 18+ · Men only
M.D. Anderson Cancer Center · Sites in United States
Ages 18+ · Men only
Alliance for Clinical Trials in Oncology · Sites in United States
Ages 18+
By country, each count listing its studies:
enzalutamide: first FDA approval 2012 (XTANDI), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 20 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 33 · Phase 2 78 · Phase 3 18 · Phase 4 7
First in 2005; this study’s year is marked. 9 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 206 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 52 across the 125 interventional studies. Of the 81 that completed or were terminated, 49 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
45 of 125 have an industry lead sponsor. The 10 most frequent:
Astellas Pharma Inc is the lead sponsor of 525 studies on the registry; 4 are open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 19 (68%) have results posted.
53 studies in Prostatic Neoplasms by Astellas Pharma Inc: 5 open now, 7 under way, 1 of them phase 3. Of 46 finished, 13 (28%) have results posted.
Among the 53 studies in Prostatic Neoplasms by Astellas Pharma Inc, this one is the 13th largest by enrollment of the 39 interventional ones that give a count, is one of 4 that started in 2016, is one of 7 in phase 4, and was the 39th registered.
Astellas Pharma Inc’s Prostatic Neoplasms studies by the year they started, since 2001.
13 of the studies testing enzalutamide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT02446405Phase 3University of SydneyEnzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer | 2026-12-31 |
| NCT05873192M.D. Anderson Cancer CenterPresurgical Phase II Study of Talazoparib in Combination With Enzalutamide in Prostate Cancer | 2026-12-31 |
| NCT03344211University of Southern CaliforniaEnzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer | 2026-12-31 |
| NCT05406999The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNeoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 125 studies testing enzalutamide in Prostatic Neoplasms, from their registry updates:
Among Astellas Pharma Inc’s 53 in Prostatic Neoplasms:
This tab as a report to print or save as PDF → With an account.
The objective of this study was to compare the efficacy and safety of the combination therapy with enzalutamide + androgen deprivation therapy (ADT) and the combination therapy with flutamide + ADT in patients with castration resistant prostate cancer who had relapsed during combined androgen blockade (CAB) therapy with bicalutamide and ADT. This study also investigated the order of alternative antiandrogen therapy (AAT) by changing the 1st line medication after relapse of prostate-specific antigen (PSA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received enzalutamide 160 mg capsules, orally once daily as 1st line of alternative antiandrogen therapy (AAT) until confirmed prostate-specific antigen (PSA) progression, other disease progression, or an intolerable adverse event. After confirmation of PSA progression, other disease progression, or an intolerable adverse event, participants received flutamide 125 mg tablets orally thrice daily after each meal as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Drug: Enzalutamide · Drug: Flutamide · Other: Androgen deprivation therapy
Participants received flutamide 125 mg tablets orally thrice daily after each meal as 1st line of AAT until confirmed PSA progression, other disease progression, or an intolerable adverse event. After confirmed PSA progression, other disease progression, or an intolerable adverse event. participants received enzalutamide 160 mg capsules orally once daily as 2nd line of AAT. Treatment with each drug was continued until the participant met any of the discontinuation criteria or until 2 years from the enrollment of the last participant (approximately 38 months).
Drug: Enzalutamide · Drug: Flutamide · Other: Androgen deprivation therapy
Oral Capsule
Also known as: Xtandi, MDV3100
Oral tablet
All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
Time to PSA Progression With 1st Line AAT (TTPP1)
TTPP1 was defined as the period from the date of randomization to the date of PSA progression in the 1st line AAT period. PSA progression was defined according to the consensus guidelines of prostate cancer clinical trials working group 2 (PCWG2). For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier (KM) estimates.
Time frame: From date of randomization to the date of PSA progression in the 1st line AAT period (Up to 38 months)
Time to PSA Progression With 2nd Line AAT (TTPP2)
TTPP2 was defined as the period from day 1 of the 2nd line AAT to the date of PSA progression with the 2nd line AAT. PSA progression was defined according to the consensus guidelines of PCWG2. For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier estimates.
Time frame: From date of randomization to the date of PSA progression in 2nd line AAT (Up to 38 months)
Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline and Up To Week 38 in Prostate Specific Antigen (PSA) Response at 1st Line AAT
PSA response was defined as PSA decreased by at least 50% or 90% from baseline when at least 3 weeks passed after the lowest PSA decreased by at least 50% or 90% from baseline in the 1st line AAT period after baseline. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time frame: Baseline and at least 3 weeks after, the lowest PSA decreased by at least 50% or 90% from baseline (Up to 38 months)
Percentage of Participants Achieving at Least 50 or 90 Percent (%) Reduction From Baseline to Week 13 in Prostate Specific Antigen (PSA) Response at 1st Line AAT
PSA response was defined as the lowest PSA at week 13 decreased by at least 50% or 90% from baseline in the 1st line AAT period. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time frame: Baseline and week 13
Time to PSA Decrease by 50% From Baseline With 1st Line AAT
Time to PSA decrease by 50% with 1st line AAT was defined as the period from the date of randomization to the day when the decrease of PSA from baseline by 50% is first identified. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time frame: From date of randomization to the day when the decrease of PSA from baseline by 50% is first identified (Up to 38 months)
Time to Treatment Failure of 1st Line AAT (TTF1)
TTF1 was defined as the period from randomization to study drug discontinuation of 1st line AAT for any reason that includes disease progression, onset of adverse events (AEs), participants request, or death. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time frame: From date of randomization to discontinuation of 1st line AAT (Up to 38 months)
Time to Treatment Failure of 2nd Line AAT (TTF2)
TTF2 was defined as the period from randomization to study drug discontinuation of 2nd line AAT for any reason that includes disease progression, onset of AEs, participants request, or death. Time to event analysis was performed using kaplan-meier estimates.
Time frame: From date of randomization to discontinuation of 2nd line AAT (Up to 38 months)
Radiographic Progression-free Survival (rPFS)
rPFS was defined as the period from randomization to the time when radiographic disease progression is observed or death of any cause during the study period, whichever occurs earlier. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
Time frame: From date of randomization to the time when radiographic disease progression is observed or death of any cause (up to 38 months)
Participants with M0 or M1 castration-resistant prostatic neoplasm that relapsed during Combined Androgen Blockade (CAB) therapy with bicalutamide were enrolled in this study.
| Milestone | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| Started | 102 | 104 |
| Maintained 1st line aat without progression | 25 | 8 |
| Completed | 73 | 93 |
| Not completed | 29 | 11 |
| Withdrew: Progressive disease | 9 | 4 |
| Withdrew: Adverse event | 12 | 3 |
| Withdrew: Physician decision | 4 | 2 |
| Withdrew: Withdrawal by subject | 2 | 1 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Death | 1 | 0 |
| Withdrew: Miscellaneous | 1 | 0 |
| Milestone | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| Started | 48 | 85 |
| Completed | 23 | 73 |
| Not completed | 25 | 12 |
| Withdrew: Progressive disease | 21 | 3 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Death | 0 | 1 |
TTPP1 was defined as the period from the date of randomization to the date of PSA progression in the 1st line AAT period. PSA progression was defined according to the consensus guidelines of prostate cancer clinical trials working group 2 (PCWG2). For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier (KM) estimates.
| Months | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| Time to PSA Progression With 1st Line AAT (TTPP1) | 21.39 (12.16 to NA) | 5.78 (4.67 to 8.54) |
TTPP2 was defined as the period from day 1 of the 2nd line AAT to the date of PSA progression with the 2nd line AAT. PSA progression was defined according to the consensus guidelines of PCWG2. For participants with PSA declines at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the nadir were documented, which was confirmed by a second consecutive value obtained 3 or more weeks later. For participants with no PSA decline at week 13, the PSA progression date was defined as the date that a ≥ 25% increase and an absolute increase of ≥ 2 ng/mL above the baseline were documented. Time to event analysis was performed using kaplan-meier estimates.
| Months | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| Time to PSA Progression With 2nd Line AAT (TTPP2) | NA (20.99 to NA) | 21.22 (14.78 to NA) |
PSA response was defined as PSA decreased by at least 50% or 90% from baseline when at least 3 weeks passed after the lowest PSA decreased by at least 50% or 90% from baseline in the 1st line AAT period after baseline. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
| Percentage of participants | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| M0/N0: (≥ 50% reduction) | 75.0 (53.3 to 90.2) | 48.0 (27.8 to 68.7) |
| M0/N1: (≥ 50% reduction) | 66.7 (9.4 to 99.2) | 0.0 (0.0 to 60.2) |
| M1: (≥ 50% reduction) | 72.0 (60.4 to 81.8) | 32.0 (21.7 to 43.8) |
| All participants: (≥ 50% reduction) | 72.5 (62.8 to 80.9) | 34.6 (25.6 to 44.6) |
| M0/N0: (≥ 90% reduction) | 62.5 (40.6 to 81.2) | 8.0 (1.0 to 26.0) |
| M0/N1: (≥ 90% reduction) | 33.3 (0.8 to 90.6) | 0.0 (0.0 to 60.2) |
| M1: (≥ 90% reduction) | 53.3 (41.4 to 64.9) | 20.0 (11.6 to 30.8) |
| All participants: (≥ 90% reduction) | 54.9 (44.7 to 64.8) | 16.3 (9.8 to 24.9) |
PSA response was defined as the lowest PSA at week 13 decreased by at least 50% or 90% from baseline in the 1st line AAT period. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
| Percentage of participants | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| M0/N0: (≥ 50% reduction) | 83.3 (62.6 to 95.3) | 40.0 (21.1 to 61.3) |
| M0/N1: (≥ 50% reduction) | 66.7 (9.4 to 99.2) | 0.0 (0.0 to 60.2) |
| M1: (≥ 50% reduction) | 72.0 (60.4 to 81.8) | 33.3 (22.9 to 45.2) |
| All participants: (≥ 50% reduction) | 74.5 (64.9 to 82.6) | 33.7 (24.7 to 43.6) |
| M0/N0: (≥ 90% reduction) | 50.0 (29.1 to 70.9) | 8.0 (1.0 to 26.0) |
| M0/N1: (≥ 90% reduction) | 33.3 (0.8 to 90.6) | 0.0 (0.0 to 60.2) |
| M1: (≥ 90% reduction) | 49.3 (37.6 to 61.1) | 18.7 (10.6 to 29.3) |
| All participants: (≥ 90% reduction) | 49.0 (39.0 to 59.1) | 15.4 (9.1 to 23.8) |
Time to PSA decrease by 50% with 1st line AAT was defined as the period from the date of randomization to the day when the decrease of PSA from baseline by 50% is first identified. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
| Months | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| M0/N0 | 2.79 (2.66 to 3.02) | 3.94 (2.79 to NA) |
| M0/N1 | 2.79 (2.56 to NA) | NA (NA to NA) |
| M1 | 2.79 (NA to NA) | 7.49 (3.02 to NA) |
TTF1 was defined as the period from randomization to study drug discontinuation of 1st line AAT for any reason that includes disease progression, onset of adverse events (AEs), participants request, or death. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
| Months | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| M0/N0 | 17.58 (10.15 to 24.11) | 7.72 (4.47 to 15.67) |
| M0/N1 | 5.55 (4.86 to 10.38) | 4.73 (1.87 to 7.62) |
| M1 | 12.02 (7.39 to 18.43) | 3.94 (3.65 to 5.55) |
TTF2 was defined as the period from randomization to study drug discontinuation of 2nd line AAT for any reason that includes disease progression, onset of AEs, participants request, or death. Time to event analysis was performed using kaplan-meier estimates.
| Months | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| Time to Treatment Failure of 2nd Line AAT (TTF2) | 23.03 (16.79 to NA) | 16.59 (13.14 to 23.95) |
rPFS was defined as the period from randomization to the time when radiographic disease progression is observed or death of any cause during the study period, whichever occurs earlier. Time to event analysis was performed using kaplan-meier estimates. Data was reported per each disease stage (M0/N0, M0/N1, M1). 1) M0/N0: No distant metastasis and no lymph node metastasis. 2) M0/N1: Without distant metastasis, but with metastasis in lymph nodes distal to the aortic bifurcation. 3) M1: With distant metastasis (including metastasis in lymph nodes proximal to the aortic bifurcation).
| Months | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT |
|---|---|---|
| M1 | NA (NA to NA) | NA (29.08 to NA) |
Collected over From of date of randomization to end of study (up to 38 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide 160mg 1st Line AAT | 1/102 (1%) | 29/102 (28.4%) | 79/102 (77.5%) |
| Enzalutamide 160mg 2nd Line AAT | 1/85 (1.2%) | 18/85 (21.2%) | 56/85 (65.9%) |
| Flutamide 375mg 1st Line AAT | 0/104 (0%) | 15/104 (14.4%) | 65/104 (62.5%) |
| Flutamide 375mg 2nd Line AAT | 0/48 (0%) | 4/48 (8.3%) | 22/48 (45.8%) |
| Event | Enzalutamide 160mg 1st Line AAT | Enzalutamide 160mg 2nd Line AAT | Flutamide 375mg 1st Line AAT | Flutamide 375mg 2nd Line AAT |
|---|---|---|---|---|
| Cerebral infarctionNervous system disorders | 3/102 | 0/85 | 1/104 | 0/48 |
| Large intestine polypGastrointestinal disorders | 0/102 | 2/85 | 0/104 | 0/48 |
| Hepatic function abnormalHepatobiliary disorders | 1/102 | 2/85 | 1/104 | 0/48 |
| Cancer painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 2/85 | 0/104 | 0/48 |
| Lung neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/102 | 2/85 | 0/104 | 0/48 |
| Cardiac failureCardiac disorders | 0/102 | 0/85 | 0/104 | 1/48 |
| Ileus paralyticGastrointestinal disorders | 0/102 | 0/85 | 0/104 | 1/48 |
| Loss of consciousnessNervous system disorders | 1/102 | 0/85 | 0/104 | 1/48 |
| DeliriumPsychiatric disorders | 0/102 | 1/85 | 0/104 | 1/48 |
| Acute kidney injuryRenal and urinary disorders | 1/102 | 0/85 | 0/104 | 1/48 |
| Event | Enzalutamide 160mg 1st Line AAT | Enzalutamide 160mg 2nd Line AAT | Flutamide 375mg 1st Line AAT | Flutamide 375mg 2nd Line AAT |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 23/102 | 12/85 | 17/104 | 2/48 |
| MalaiseGeneral disorders | 15/102 | 17/85 | 4/104 | 2/48 |
| FallInjury, poisoning and procedural complications | 18/102 | 10/85 | 4/104 | 1/48 |
| FatigueGeneral disorders | 15/102 | 8/85 | 3/104 | 0/48 |
| Back painMusculoskeletal and connective tissue disorders | 15/102 | 4/85 | 6/104 | 1/48 |
| ConstipationGastrointestinal disorders | 14/102 | 2/85 | 3/104 | 0/48 |
| HypertensionVascular disorders | 13/102 | 5/85 | 2/104 | 0/48 |
| DiarrhoeaGastrointestinal disorders | 7/102 | 2/85 | 12/104 | 6/48 |
| Decreased appetiteMetabolism and nutrition disorders | 11/102 | 8/85 | 4/104 | 2/48 |
| Hepatic function abnormalHepatobiliary disorders | 2/102 | 2/85 | 9/104 | 2/48 |
Intent-to-Treat (ITT) population was defined as all participants randomized in this study.
| Age, Continuous(years) | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT | Total |
|---|---|---|---|
| Mean | 74.4 ± 7.6 | 74.1 ± 7.6 | 74.2 ± 7.6 |
| Sex: Female, Male(Participants) | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 102 | 104 | 206 |
| Race and Ethnicity Not Collected(Participants) | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT | Total |
|---|---|---|---|
| Count of participants | — | — | 0 |
| Disease Stages at Randomization(Participants) | Enzalutamide 160 mg 1st Line AAT/Flutamide 375 mg 2nd Line AAT | Flutamide 375 mg 1st Line AAT/Enzaltumide 160 mg 2nd Line AAT | Total |
|---|---|---|---|
| M0/N0 | 24 | 25 | 49 |
| M0/N1 | 3 | 4 | 7 |
| M1 | 75 | 75 | 150 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Nov 2016 to primary completion in Mar 2020, 40 months.
Results were first posted in May 2021, 1 year 1 month after primary completion.
Of 52 phase 4 interventional studies under Prostatic Neoplasms, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 67. This study's 40 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Enzalutamide · Flutamide